Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pcDNA3.3-SARS2-B.1.617.2 Citations (16)

Originally described in: Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J Sci Transl Med. 2021 Oct 20;13(616):eabj5413. doi: 10.1126/scitranslmed.abj5413. Epub 2021 Oct 20. PubMed Journal

Articles Citing pcDNA3.3-SARS2-B.1.617.2

Articles
LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. Song J, Chow RD, Pena-Hernandez M, Zhang L, Loeb SA, So EY, Liang OD, Wilen CB, Lee S. bioRxiv. 2021 Nov 24. doi: 10.1101/2021.11.23.469714. PubMed
Targeting an evolutionarily conserved "E-L-L" motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2. Jana ID, Bhttacharya P, Mayilsamy K, Banerjee S, Bhattacharje G, Das S, Aditya S, Ghosh A, McGill AR, Srikrishnan S, Das AK, Basak A, Mohapatra SS, Chandran B, Bhimsaria D, Mohapatra S, Roy A, Mondal A. bioRxiv. 2022 Mar 21. doi: 10.1101/2022.03.16.484554. PubMed
Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody. Sulea T, Baardsnes J, Stuible M, Rohani N, Tran A, Parat M, Cepero Donates Y, Duchesne M, Plante P, Kour G, Durocher Y. PLoS One. 2022 Mar 30;17(3):e0266250. doi: 10.1371/journal.pone.0266250. eCollection 2022. PubMed
SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Shah M, Ung Moon S, Hyun Kim J, Thanh Thao T, Goo Woo H. Comput Struct Biotechnol J. 2022;20:2042-2056. doi: 10.1016/j.csbj.2022.04.030. Epub 2022 Apr 26. PubMed
High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1. Kuzikov M, Woens J, Zaliani A, Hambach J, Eden T, Fehse B, Ellinger B, Riecken K. Biomed Pharmacother. 2022 Jul;151:113104. doi: 10.1016/j.biopha.2022.113104. Epub 2022 May 16. PubMed
Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. Chiu CH, Chang YH, Chang FY, Hung YJ, Liao CL, Chiu KC, Tsai PL, Chang TW, Yen LC. Front Cell Infect Microbiol. 2022 May 17;12:862656. doi: 10.3389/fcimb.2022.862656. eCollection 2022. PubMed
Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Vikkurthi R, Ansari A, Pai AR, Jha SN, Sachan S, Pandit S, Nikam B, Kalia A, Jit BP, Parray HA, Singh S, Kshetrapal P, Wadhwa N, Shrivastava T, Coshic P, Kumar S, Sharma P, Sharma N, Taneja J, Pandey AK, Sharma A, Thiruvengadam R, Grifoni A, Weiskopf D, Sette A, Bhatnagar S, Gupta N. Nat Microbiol. 2022 Jul;7(7):974-985. doi: 10.1038/s41564-022-01161-5. Epub 2022 Jun 9. PubMed
Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. Duan LJ, Jiang WG, Wang ZY, Yao L, Zhu KL, Meng QC, Wang BS, Li LB, Wang GL, Ma MJ. iScience. 2022 Sep 16;25(9):104886. doi: 10.1016/j.isci.2022.104886. Epub 2022 Aug 9. PubMed
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH, Chang YH, Tao CW, Chang FY, Chiu KC, Chang TW, Yen LC. Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25. PubMed
LRRC15 inhibits SARS-CoV-2 cellular entry in trans. Song J, Chow RD, Pena-Hernandez MA, Zhang L, Loeb SA, So EY, Liang OD, Ren P, Chen S, Wilen CB, Lee S. PLoS Biol. 2022 Oct 13;20(10):e3001805. doi: 10.1371/journal.pbio.3001805. eCollection 2022 Oct. PubMed
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J. Cell Host Microbe. 2022 Nov 4. pii: S1931-3128(22)00523-6. doi: 10.1016/j.chom.2022.10.010. PubMed

Associated Plasmids
Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. Azuma H, Kawano Y, Shitaoka K, Kawahara T, Ito A, Higashiura A, Kitajima Y, Ohki S, Yasuda T. Int Immunol. 2023 Apr 4;35(4):197-207. doi: 10.1093/intimm/dxac055. PubMed
Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. Xiang Y, Zhai G, Li Y, Wang M, Chen X, Wang R, Xie H, Zhang W, Ge G, Zhang Q, Xu Y, Caflisch A, Xu J, Chen H, Chen L. Int J Biol Macromol. 2023 Jan 31;226:780-792. doi: 10.1016/j.ijbiomac.2022.12.057. Epub 2022 Dec 12. PubMed
Inhibitory Activity of Saussurea costus Extract against Bacteria, Candida, Herpes, and SARS-CoV-2. Idriss H, Siddig B, Gonzalez-Maldonado P, Elkhair HM, Alakhras AI, Abdallah EM, Elzupir AO, Sotelo PH. Plants (Basel). 2023 Jan 19;12(3):460. doi: 10.3390/plants12030460. PubMed
Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. Shitaoka K, Higashiura A, Kawano Y, Yamamoto A, Mizoguchi Y, Hashiguchi T, Nishimichi N, Huang S, Ito A, Ohki S, Kanda M, Taniguchi T, Yoshizato R, Azuma H, Kitajima Y, Yokosaki Y, Okada S, Sakaguchi T, Yasuda T. Commun Biol. 2023 Apr 11;6(1):395. doi: 10.1038/s42003-023-04782-6. PubMed
The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection. Bains A, Guan W, LiWang PJ. Viruses. 2023 Sep 9;15(9):1901. doi: 10.3390/v15091901. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.